Aimmune Therapeutics (AIMT) Reaches $21.81 After 7.00% Up Move, Tortoise Power & Energy Infrastructure Fund (TPZ) Has 1.5 Sentiment

July 17, 2017 - By Winifred Garcia

Tortoise Power and Energy Infrastructure Fund, Inc. is a non-diversified, closed-end management investment company. The company has market cap of $146.02 million. The Fund’s primary investment objective is to provide a high level of current income. It currently has negative earnings. The Fund’s secondary objective is capital appreciation.

The stock of Aimmune Therapeutics Inc (NASDAQ:AIMT) is a huge mover today! About 134,785 shares traded. Aimmune Therapeutics Inc (NASDAQ:AIMT) has risen 32.49% since July 17, 2016 and is uptrending. It has outperformed by 15.79% the S&P500.The move comes after 6 months positive chart setup for the $1.10B company. It was reported on Jul, 17 by Barchart.com. We have $23.34 PT which if reached, will make NASDAQ:AIMT worth $77.00 million more.

Among 4 analysts covering Aimmune Therapeutics (NASDAQ:AIMT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aimmune Therapeutics has $44 highest and $35 lowest target. $39.33’s average target is 80.33% above currents $21.81 stock price. Aimmune Therapeutics had 5 analyst reports since August 31, 2015 according to SRatingsIntel. The rating was maintained by Piper Jaffray with “Overweight” on Tuesday, November 17. The stock of Aimmune Therapeutics Inc (NASDAQ:AIMT) has “Mkt Outperform” rating given on Monday, September 26 by JMP Securities. Credit Suisse initiated Aimmune Therapeutics Inc (NASDAQ:AIMT) rating on Monday, August 31. Credit Suisse has “Outperform” rating and $44 target. Piper Jaffray initiated the stock with “Overweight” rating in Monday, August 31 report. Bank of America initiated Aimmune Therapeutics Inc (NASDAQ:AIMT) rating on Monday, August 31. Bank of America has “Buy” rating and $36 target.

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical firm developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The company has market cap of $1.10 billion. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy , is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. It currently has negative earnings. The Company’s lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy.

Analysts await Aimmune Therapeutics Inc (NASDAQ:AIMT) to report earnings on August, 9. They expect $-0.64 earnings per share, down 48.84% or $0.21 from last year’s $-0.43 per share. After $-0.52 actual earnings per share reported by Aimmune Therapeutics Inc for the previous quarter, Wall Street now forecasts 23.08% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: